Dupilumab
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Allergies Food Milk
Conditions
Allergies Food Milk
Trial Timeline
Oct 18, 2021 → Feb 25, 2025
NCT ID
NCT04148352About Dupilumab
Dupilumab is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Allergies Food Milk. The current trial status is terminated. This product is registered under clinical trial identifier NCT04148352. Target conditions include Allergies Food Milk.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06631677 | Pre-clinical | Completed |
| NCT04776694 | Pre-clinical | Completed |
| NCT06226610 | Phase 2 | Recruiting |
| NCT05042258 | Approved | Recruiting |
| NCT06012448 | Approved | Completed |
| NCT05720325 | Phase 2 | Recruiting |
| NCT05268107 | Approved | Recruiting |
| NCT05128383 | Phase 2 | Completed |
| NCT05265234 | Approved | UNKNOWN |
| NCT05036733 | Approved | Completed |
| NCT05246267 | Pre-clinical | Recruiting |
| NCT04148352 | Phase 2 | Terminated |
| NCT04296864 | Phase 2 | UNKNOWN |
| NCT03935971 | Approved | Active |
| NCT03886493 | Phase 2 | Terminated |
| NCT03667014 | Approved | Completed |
Competing Products
5 competing products in Allergies Food Milk
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0524 | Merck | Phase 2 | 52 |
| Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA) + Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA) | Sandoz Group | Phase 1 | 30 |
| Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA) + Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA) | Sandoz Group | Phase 1 | 30 |
| Desloratadine + Zyrtec® (cetirizine) | Organon | Approved | 80 |
| Desloratadine + Zyrtec® (cetirizine) | Organon | Approved | 80 |